Summary HER2/neu-derived peptides inducing MHC class II-restricted CD4+ T helper lymphocyte (Th) responses, although critical for tumour rejection, are not thoroughly characterized. Here, we report the generation and characterization of CD4+ T cell clones specifically recognizing a HER-2/neu-derived peptide (776)(777)(778)(779)(780)(781)(782)(783)(784)(785)(786)(787)(788) ]. Such clones yielded specific proliferative and cytokine [gamma-interferon(IFN)-γ] responses when challenged with autologous dendritic cells (DCs) loaded with . By performing blocking studies with monoclonal antibodies (MAbs) and by using DCs from allogeneic donors sharing certain HLA-DR alleles, we found that HER2(776-788) is a promiscuous peptide presented, at least, by DRB5*0101, DRB1*0701 and DRB1*0405 alleles. One TCRVbeta6.7+ clone recognized the HLA-DRB5*0101+ FM3 melanoma cell line transfected with a full length HER-2/neu cDNA. Moreover, this clone recognized the HER-2/neu+ SKBR3 breast cancer cell line induced to express HLA-DR, thus demonstrating that HER2(776-788) represents a naturally processed and presented epitope. Our data demonstrate that helper peptide HER2(776-788) represents a promiscuous epitope binding to at least three HLA-DR alleles, thus offering a broad population coverage. 
Increasing evidence from both murine and human studies has indicated that optimal antitumour responses require the participation of both CD4+ Th and CD8+ cytotoxic T lymphocyte (CTL) (Pardoll and Topalian, 1998) . Originally it was thought that the importance of Th cells was due to production of cytokines, particularly interleukin (IL)-2, which provided growth and differentiation signals for precursor CTL to become effector CTL lysing the autologous tumour (Simpson and Gordon, 1977; Keene and Forman, 1982) . More recent reports from several laboratories including our own, however, have ascribed another function to CD4+ T lymphocytes, namely the activation of antigen presenting cells (APCs) so that they can effectively stimulate precursor CTL to become effector CTL (Ridge et al, 1998; Schoenberger et al, 1998; Baxevanis et al, 2000) . Recognition of the essential role of CD4+ T lymphocytes for developing effective antitumour responses has been accompanied by the identification of antigens (Ags) on human tumours. Several MHC class I-restricted peptide epitopes are derived from tumour Ags such as tyrosinase, gp100, Melan-A, MART-1, MAGE-3 and NY-ESO-1 which have also been demonstrated also to contain MHC class II-restricted epitopes recognized by CD4+ T lymphocytes (Wang and Rosenberg, 1999; Jaeger et al, 2000) .
The HER-2/neu proto-oncogene encodes a transmembrane glycoprotein with extensive homology to epidermal growth factor receptor whose cytoplasmic domain has tyrosine kinase activity (Hung and Lau, 1999) . Over-expression of HER-2/neu on many adenocarcinomas of breast and ovary is correlated with poor prognosis (Schultz and Weber, 1999) . In the past few years several peptide epitopes from HER-2/neu have been clearly demonstrated to be recognized by ovarian (Ioannides et al, 1991; Peoples et al, 1994; Yoshino et al, 1994; Fisk et al, 1995; Rongcun et al, 1999) and breast Peoples et al, 1995) cancer specific CTL. In addition to the MHC class I-restricted epitopes, there is growing evidence that HER-2/neu protein also contains helper epitopes. Thus, it has already been shown that: (i) some patients with HER-2/neu positive cancers produce IgG antibodies against the HER-2/neu protein (Disis et al, 1994) and (ii) CD4 + T cells from HER-2/neu-positive cancer patients can proliferate and produce cytokines in response to synthetic peptides or recombinant HER-2/neu protein (Disis et al, 1997; Fisk et al, 1997; Tuttle et al, 1998) . It is expected that using CTL and Th peptide epitopes together in therapeutic vaccines may enhance their effectiveness in clinical trials.
The purpose of this study was to examine the potential use of HER2(776-788) as a helper epitope and the identification of its potential promiscuity (broad MHC restriction), so as to improve the design of vaccination protocols of CTL-based immunotherapy for tumours over-expressing HER-2/neu. We report here that HER2(776-788) is a helper peptide naturally processed and specifically recognized on tumour cells by CD4+ T cell clones in vitro. HER2(776-788)-activated CD4 + T cells secrete large amounts of IFN-γ, but not IL-4 or IL-10, which is suggestive of a Th1 function of such cells stimulated by this peptide. One of the clones recognized HER2(776-788) in the context of either Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope HLA-DRB1*0405, DRB1*0701 and DRB5*0101 indicating a high degree of promiscuity both in peptide binding to the class II molecule, and in recognition of different MHC/peptide complexes by the same TCR. These results may encourage the use of the HER2(776-788) peptide along with HER-2/neu-derived CTL epitopes in vaccination protocols for cancer patients of different MHC types whose tumours over-express HER-2/neu.
MATERIALS AND METHODS

Cell lines
The human breast adenocarcinoma cell line SKBR3 (American Type Culture Collection, Manassas, VA) was cultured in McCoy's 5A medium supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine and 50 µg/ml gentamicin (all purchased from Life Technologies, Gaithersburg, MD). SKBR3 cells were induced to express HLA-DR molecules after a 4-day incubation with 150 U/ml human recombinant IFN-γ (BoehringerMannheim, Mannheim, Germany) and human recombinant tumour necrosis factor (TNF)-α 100U/ml (R&D System, Abingdon, UK) in a CO 2 incubator. The human melanoma cell line FM3 (a kind gift of Dr J Zeuthen, Dept of Tumor Cell Biology, Danish Cancer Society Research Center, Copenhagen) was grown in RPMI 1640 (Life Technologies) with 10% FBS 2mM Lglutamine and 50 µg/ml gentamicin (complete medium).
Purification of CD4
+ T cells CD4 + T cells were isolated from PBMCs collected by standard procedures from a healthy volunteer [HLA serotyping: HLA-A2, A3, B44, B47, Cw6, DR15(2), DR4, DR51, DR53, DQ6(1), DQ8(3)].
Highly purified CD4 + T cells (>98% purity) were isolated using Dynabeads (CD4 Positive Isolation Kit; Dynal, Oslo, Norway), as recently described (Baxevanis et al, 1999) .
Generation of dendritic cells
DCs autologous to the CD4 + T cells were generated from the adherent fraction of freshly isolated PBMCs. Briefly, 4 × 10 6 PBMCs in 2 ml X-VIVO 15 (BioWhittaker, Walkersville, MD) were plated in 6-well plates (Costar, Corning Inc., NY) and incubated for 2 h in a CO 2 incubator. Non adherent cells were gently washed out with Hanks' Balanced Salt Solution (HBSS; Life Technologies). The remaining plastic adherent cells were cultured in 2 ml X-VIVO 15 medium supplemented with 1000 IU/ml IL-4 (R&D Systems, Europe) and 1000 IU/ml granulocyte macrophage-colony stimulating factor (GM-CSF) (Immunex, Seattle, WA). Fresh medium (2 ml) and cytokines were added on days 2 and 4. For induction of maturation, TNF-α was added at 10 ng/ml on day 6. The nonadherent cell population was used on day 7 as a source of enriched mature dendritic cells or cryopreserved for later use. The percentage of mature DCs recorded was > 50%, as based on the CD3-, CD14-, CD16-, CD20-, CD40+, CD80+, CD83+, CD86+, and HLA-DR+ phenotype analysed by flow cytometry. Mature DCs were used as APCs pretreated with 70 µg/ml mitomycin C (Kyowa, Tokyo, Japan) for 45 min at 37˚C.
After extensive wash with HBSS, DCs were pulsed with the appropriate concentration of peptide for 4 h at 37˚C.
HLA alleles presented in Table 1 were determined by standard genotyping methods. Alleles HLA-DRB1*0401, *0404 and *0405 correspond to DR4, DRB1*1501 to DR15(2), DRB1*1101, 1104 to DR11(5), DRB*1601 to DR16(2), DRB1*0301 to DR17(3), DRB1*1001 to DR10, DRB1*1401 to DR14(6), DRB1*0701 to DR7, DRB5*0101 to DR51, DRB4*0101 to DR53, DRB3*0101 and *0201 to DR52.
Peptide synthesis
Synthesis of the HER-2(776-788) (GSPYVSRLLGICL) peptide and of control peptides HER-2(884-899) (VPIKWMALE-SILRRRF) (Fisk et al, 1997) , gp100(44-59) (WNRQ-LYPEWTEAQRLD) (Halder et al, 1997) and tyrosinase(448-462) (DYSYLQDSDPDSFQD) (Topalian et al, 1996) was performed with an Ecosyn P peptide synthesizer (Eppendorf-Biotronik, Hamburg, Germany), using the Fmoc strategy and a 4-alcoxybenzyl alcohol resin. The peptides were assayed for purity by analytical HPLC, amino acid analysis and matrix-assisted laser desorption mass spectrometry. All peptides were determined to be > 95% pure. Peptides were lyophilized, dissolved in phosphate-buffered saline (PBS), aliquoted at 2 mg/ml and stored frozen at -20˚C until use (Reicher et al, 1996) .
Monoclonal antibodies and immunophenotyping
MAbs to TCR α/β common and variable regions: Vβ3.1, Vβ5(a), Vβ6.7, Vβ7.1, Vβ8(a), Vβ12, Vβ13 and Vβ17 conjugated with FITC were obtained from Endogen (Boston, MA). Anti-CD83 conjugated with PE MAb was obtained from Caltag Laboratories (Burlingame, CA). Anti-TCR Vβ9 conjugated with PE and anti-TCR Vβ11, Vβ5.1, Vβ21, Vβ13.6, Vβ7, Vβ22, Vβ16, Vβ14, Vβ20, Vβ2 conjugated with FITC were purchased from Serotec Ltd (Oxford, UK). Isotype matched anti-IgG conjugated with FITC (IgG 1 , clone G18-145) was purchased from Becton Dickinson (Mountain View, CA). All other MAbs were obtained from PharMingen (San Diego, CA). Anti-CD4, -CD8, -CD16, -CD20, -CD40 and anti-CD80 were conjugated with FITC. Anti-CD3, -CD14, -CD56, -CD86, -HLA-DR and anti-TCR Vβ23 MAbs were conjugated with PE. Samples were analysed using FACScan (Becton Dickinson) and CellQuest analysis software. For blocking experiments, purified azide-free anti-HLA-DR (clone L243, IgG2a, κ), anti-TNP, (clone G155-178, IgG2a, κ) (both from PharMingen), HLA-DP (clone B7/21, Becton Dickinson) and anti-HLA-A,B,C (clone W6/32) and anti-HLA-DQ (clone SPVL3) (both from Serotec) were used.
Generation of CD4+ T cell line and clones specific for HER2(776-788)
Highly purified CD4+ T cells were plated in 96-well U-bottom plates (Costar) at 5 × 10 4 cells/well with 10 4 well autologous mature DCs were pulsed with 25 µg/ml HER-2 (776-788) peptide. Cultures were set up in a final volume of 200 µl X-VIVO 15 medium supplemented with 1% autologous heat-inactivated plasma, 10 ng/ml IL-7 (R&D systems) and 100 pg/ml IL-12 (R&D systems) in a CO 2 incubator. Growing cultures were restimulated at weekly intervals with DCs pulsed with 5 µg/ml of the peptide. After 3 days from the first restimulation, IL-2 (Chiron Corporation, California) was added at 10 IU/ml. Peptide-specific T cell clones were obtained from this bulk culture by limiting dilution. Cloning was accomplished in X-VIVO 15 medium supplemented with 0.5 µg/ml PHA (Sigma), 1 IU/ml IL-2, 10 ng/ml IL-7, 100 pg/ml IL-12 and mitomycin C treated allogeneic PBMCs as feeders (2 × 10 4 /well).
Transfection of the FM3 cell line
FM3 cells were co-transfected with a pSV2-c-erbB2 construct (kindly provided by Dr Mien-Chie Hung, MD Anderson Cancer Ctr, Houston, Texas) and a pSV2neo plasmid using DNAcalcium phosphate co-precipitates as described (Graham and van der Eb, 1973) . Selection with G-418 (500 µg/ml) was started 48 h later. For cloning the cells were distributed into 96-well flat bottom tissue culture plates (Costar) and stable transfectants were selected. HER-2/neu-transfected FM3 lines were subcloned until all cells were found to express HER-2/neu (thereafter referred to as FM3/HER) as detected by FACS using FITC-conjugated anti-HER-2/neu MAb (clone Neu 24.7) recognizing the extracellular domain of HER-2/neu (Becton Dickinson).
Proliferation assay
Responder CD4 + T cells (2×10 4 cells/well) were co-cultured with peptide (5 µg/ml) pulsed or unpulsed autologous DCs (2×10 3 cells/well) as APCs in 96-well U-bottom plates in a final volume of 200 µl X-VIVO 15 medium supplemented with 10 ng/ml IL-7 and 100 pg/ml IL-12. FM3 or FM3/HER cells and SKBR3 cells (non-treated or treated with IFN-γ plus TNF-α) were also used as APCs at 2 × 10 3 cells/well. MAbs, wherever indicated, were added at 10 µg/ml final concentration throughout the culture period. On day 4, 1 µCi/well tritiated thymidine ( 
ELISPOT assay
96-well flat-bottomed Immobilon-P PVDF plates (Multi-Screen-IP, Millipore, Bedford, MA) were coated overnight at 4˚C with 2 µg/ml anti-IFN-γ MAb (NIB42, PharMingen). Responder T cells were cultured in the 96-well nitrocellulose pre-coated plates at 2×10 4 cells/well with autologous peptide (5 µg/ml) pulsed or unpulsed DCs at 2×10 3 cells/well in 200 µl X-VIVO 15 medium supplemented with 1 IU/ml IL-2, 10ng/ml IL-7 and 100 pg/ml IL-12 for 24 h at 37˚C. After incubation, the plates were washed extensively (with a solution of 0.05% Tween 20/PBS) and supplemented with the biotinylated anti-IFN-γ MAb (4S.B3, PharMingen). Plates were incubated for 2 h at room temperature, washed and developed with alkaline phosphatase-conjugated streptavidin (Bio-Rad Laboratories, Hercules, CA) for another 1 h. After washing, BCIP/NTB substrate (Bio-Rad) was used to develop dark-violet spots. Spots were counted under a stereomicroscope (Zeiss, Germany). % inhibition of IFN-γ spots by the HLA-DR MAb was calculated as follows:
no. of spots w/o MAb -no. of spots with MAb ϫ 100 no. of spots w/o MAb response was detected in the presence of autologous DCs pulsed with this peptide which was to a great extent blocked with an anti-HLA-DR (MHC class II) MAb, but not with an isotype matched control MAb or an anti-HLA-A,B,C (MHC class I) MAb (Figure 1 ). MAb recognizing monomorphic determinants on MHC class II molecules DP and DQ remained also without any effect (Figure 1 ). The specificity of this CD4+ T cell line was further tested against autologous DCs pulsed with irrelevant peptides from HER-2/neu [HER2(884-899)], gp100 [gp(44-59)] or tyrosinase [tyro(448-462) ] all of which have been reported to be recognized by CD4+ T cells in the context of HLA-DR molecules (Topalian et al, 1996; Halder et al, 1997; Kobayashi et al, 2000) . As shown in Figure 2 , none of these could significantly stimulate proliferative response in the HER2(776-788) specific CD4+ T cell line. The same line was unable to recognize the HLA-DR+, HER-2/neu negative(-) FM3 melanoma cell line. However, it proliferated strongly upon stimulation with HER-2/neu-transfected FM3 cells (FM3/HER) and this response was also substantially blocked in the presence of the anti-HLA-DR MAb (Figure 2 ). These data suggested that the CD4+ T line specifically recognizes the HER-2/neu peptide. Moreover, the significant recognition of FM3/HER cells suggests that HER2(776-788) represents a naturally processed and presented epitope.
Generation and characterization of HER2(776-788)-specific CD4+ T cell clones
To better characterize the HER-2/neu peptide-specific response, CD4+ T cell clones were generated. The CD4+ T line was cloned by limiting dilution using allogeneic PBMCs as feeders. Of the clones generated, eight proliferated in response to HER2(776-788)-pulsed autologous DCs with a SI greater than 1.5 (range: 1.5-4.9) (Figure 3) . Moreover, all clones could recognize the FM3/HER, but not the wild-type FM3 cells (SI range:1.7-4.9) (Figure 3 ). HER2(776-788) peptide recognition was confirmed by using ELISPOT assays. The same clones which significantly proliferated in response to autologous DCs pulsed with HER2(776-788) produced significant numbers of IFN-γ spots when similarly stimulated (Figure 4) . The SI observed in these experiments ranged between 1.8 and 7.7 IFN-γ spots were considered significant when the difference between the mean number from each peptide-stimulated culture (every clone was tested in duplicates) was higher than the mean number from all unstimulated cultures (mean value ± SD from eight cultures:33 ± 7) plus 2SD (i.e. > 47), which was the case in all clones tested. Similar to their parental CD4+ T-cell line, all clones recognized HER2(776-788) in the context of HLA-DR since their production of IFN-γ spots was greatly inhibited when an anti-HLA-DR MAb was added at culture initiation (range of inhibition:46-60%). CD4+ T cell clone 2.1 was propagated in vitro and functionally characterized further. This clone was highly sensitive, recognizing autologous HER2(776-788)-pulsed DCs with a half-maximal proliferation at 0.8 µg/ml of the peptide ( Figure 5 , filled symbol). Anti-HLA-DR MAb significantly blocked the proliferation at all peptide doses tested, thus proving that there was no mitogenic effect mediated by the peptide at doses higher than 0.5 µg/ml ( Figure 5 , open symbols). The same clone also recognized the peptide naturally processed and presented by both the FM3/HER melanoma cells and the HER-2/neu+ SKBR3 breast cancer cells induced to express HLA-DR upon preincubation with IFN-γ and TNF-α. This was shown by means of proliferation ( Figure 6A ) and IFN-γ secretion ( Figure 6B ). No IL-4 or IL-10 was produced by clone 2.1 in response to FM3/HER and SKBR3 treated cells (data not shown). Phenotypic analysis of clone 2.1 demonstrated that this was CD4+TCRVB6.7+ (Figure 7 ). This clone did not express CD8, CD56 or CD16. In addition, when tested with a series of TCRBV MAbs other than anti-TCRVβ6.7 (i.e. Vβ3.1, Vβ5(α), Vβ7.1, Vβ8(α), Vβ12, Vβ13, Vβ17, Vβ11, Vβ5.1, Vβ21, Vβ13.6, Vβ7, Vβ22, Vβ16, Vβ14, Vβ20, Vβ2 and Vβ23) it was also found negative (data not shown).
The data so far suggested that HER2(776-788) is presented in the context of HLA-DR and in particular of the HLA-DRB5*0101 allele which was shared between the FM3 melanoma cell line and the donor of the T cell line (donor 1; Table 1 ). However, this particular DR-allele was not identified in the SKBR3 cells which express DRB1*0701, 1302, DR52 and DR53 after IFN-γ plus TNF-α-treatment but nonetheless stimulate the clone (Table 1) . Therefore, to identify the HLA-DR alleles able to present the peptide, we tested additional DCs from different donors for their capacity to present this particular peptide to clone 2.1. We found that these were capable of presenting the peptide only when expressing one of the alleles: DR5*0101 (donors 1-3), DRB1*0405 (donors 11,12) or DRB1*0701 (donors 13, 14) (SI range: 2.6-4.7) ( Table 1) . From the same table it can be easily seen that HER2(776-788) was not recognized by clone 2.1 when presented by DRB1*0301 (donors 5,6), DRB1*0401 (donors 
DISCUSSION
The data presented herein characterize CD4+ T cell responses to HER2(776-788), show direct recognition of this epitope on HER-2/neu+ tumours and provide a rational basis for its use in T-cell based cancer immunotherapy together with MHC class I HER2/neu epitopes. In particular, we showed at the clonal level that HER2(776-788) is capable of specifically activating CD4+ T lymphocytes to strongly proliferate and produce high levels of IFN-γ. By using the FM3 melanoma cell line transfected with HER-2/neu (FM3/HER), as well as the HER2/neu+ SKBR3 breast cancer cell line induced to express HLA class II molecules, we demonstrated that HER2(776-788) represents a naturally processed and presented epitope. Last, we have shown that the same peptide was recognized by a CD4+ T lymphocyte clone in the context of three different HLA-DR alleles, indicating a high degree of histocompatibility and TCR promiscuity. Our studies show that HER2(776-788) can be recognized by a monoclonal CD4+ T lymphocyte line, clone 2.1, in the context of at least three different HLA-DR alleles, namely DRB5*0101, DRB1*0701 and DRB1*0405. Southwood et al (1998) suggested a motif for promiscuous binding peptides, characterized by a large aromatic or hydrophobic residue in position 1 (p1) and a small, noncharged residue in position 6 (p6). HER2(776-788) fulfils these criteria, as it bears Tyr and Val, either of which could be a potential candidate for p1 and also Leu and Gly that could fit at p6. DRB5*0101 and DRB1*0701 alleles are characterized by largely overlapping peptide-binding repertoires and they belong to a single DR supertype according to Southwood et al (1998) . The same peptides also exhibit significant frequencies of crossreactivity with a group of three other alleles including DRB1*0405 (Southwood et al, 1998) . Taken together all these findings satisfactorily explain the binding of HER2 (776) (777) (778) (779) (780) (781) (782) (783) (784) (785) (786) (787) (788) to the three different DR alleles. Considering also recent data published by Anderson et al (2000) who could induce a response to HER2(776-788) in two donors sharing HLA-DR11 molecule we may ascribe a high degree of promiscuity to this particular peptide. A similar finding has been recently described by Kobayashi et al (2000) which demonstrated recognition of HER2/neu-derived peptide (883-899) presented by HLA-DR1, HLA-DR4, HLA-DR52 and HLA-DR53 molecules.
Despite the high degree of specificity of ligand recognition by TCRs, several reports have described antigen specific T cells that can recognize and respond to diverse MHC molecules (Karr et al, 1991; Hemmer et al, 2000) . Doherty et al (1998) have reported the recognition of a herpes simplex virus peptide by a T lymphocyte clone presented in the context of several DR alleles. Hypervariable regions HVR3 of DRβ polypeptides encompassing residues 67-71 and in particular residue 71 have been demonstrated to exert a central role in peptide binding and allorecognition (Coppin et al, 1993; Martinez-Soria et al, 1994; McKinney et al, 1994) . In addition, position 86 has also been described to affect TCR allorecognition (Busch et al, 1991; Demotz et al, 1993; Zeliswewski et al, 1993) . HLA-DRB5*0101, DRB1*0701 and DRB1*0405 alleles display largely overlapping aminoacid sequences at positions 67-71 and 86 (Table 2 ) and this may account for the recognition by the same TCR of the peptide complexed to distinct MHC molecules.
The procedure described here proved to be efficient for optimal activation of anti-HER2 (776-788) CD4+ T cell precursors present in the PBMC from our healthy donor, and for the resulting isolation of the peptide-specific CD4+ T lymphocyte clones. Bulk CD4+ T lymphocytes proliferated specifically in an HLA-DR restricted fashion with high stimulation indices in response to autologous DCs pulsed with HER2(776-788). T cell clones established from these cells strongly proliferated and produced high levels of IFN-γ in response to autologous DCs pulsed with the HER2(776-788) peptide, suggesting that under the conditions used HER2(776-788) peptide functions as a Th peptide. Clone 2.1, which could be further propagated, was used to 
For more details see ref. (Demotz et al, 1993; McKinney et al, 1994; Doherty et al, 1998) . confirm the specificity against the naturally processed HER-2/neuderived peptides. For this, the HLA-DR51+ FM3 melanoma cell line was transfected with a full-length HER-2/neu cDNA (FM3/HER) and specific recognition by this particular clone measured as proliferation and IFN-γ (but not IL-4 or IL-10) secretion was shown. That HER2(776-788) is a naturally processed and presented peptide was confirmed by using the SKBR3 breast cancer cell line, which overexpresses HER-2/neu without enforced expression by transfection. This cell line expresses, in our hands, the HLA-DR7, -13, -52 and -53 alleles upon treatment with a combination of IFN-γ plus TNF-α (Table 1 ) and exhibits enhanced expression of costimulatory molecules CD80 and CD86 (unpublished data). Clone 2.1 recognized the IFN-γ plus TNF-α-treated SKBR3 cells in a fashion similar to that with the FM3/HER cells (Figure 6 ), thus confirming that HER2(776-788) is naturally processed and presented on the surface of carcinomas. This again suggests that HER-2/neu possesses lysosomal targeting sequences that enables it to present its peptides in the context of class II molecules. Indeed, some patients with breast cancer produce anti-HER-2/neu IgG antibodies (Cheever et al, 1995) , suggesting that HER-2/neu is presented to CD4+ T lymphocytes in vivo. Since breast tumour cells usually do not express class II molecules, this can be achieved by the uptake of tumour cell apoptotic bodies by macrophages or dendritic cells. The HER-2/neu molecule therefore represents a source of naturally processed and presented peptides capable of stimulating both CD8+ and CD4+ T-lymphocyte responses in vivo. Based on recent data from us (Baxevanis et al, 2000) and others (Ridge et al, 1998; Schoenberger et al, 1998) on CTL-Th collaboration models, it may be hypothesized that HER-2/neu specific CD4+ T lymphocytes can function in vivo as 'activators' of APCs so that they can stimulate directly HER-2/neu recognizing CD8+ T lymphocytes to become effector CTLs. Work is now in progress in our laboratory to address this hypothesis.
Taken together the data presented in this report strongly suggest that peptide HER2(776-788) represents a candidate helper epitope to be included in vaccine preparation consisting of HER-2/neu peptides presented by MHC class I and class II molecules. With such formulations vaccine-induced HER-2/neu-specific CD4+ T-lymphocyte responses may synergize with vaccine-induced CTL, resulting in improved antitumour responses. The finding that this peptide is presented in the context of three DR alleles is advantageous since: (i) it may induce higher frequency of clones recognizing it and thus a more massive anti-tumour response; and (ii) it offers a broad population coverage. The identification of tumour protein-derived Th epitopes will be useful for the design of clinical protocols aiming at the improvement of clinical results in cancer immunotherapy. 
